DK1423525T3 - Rekombinant MVA, der kan eksprimere HCV-strukturantigener - Google Patents

Rekombinant MVA, der kan eksprimere HCV-strukturantigener

Info

Publication number
DK1423525T3
DK1423525T3 DK02797955T DK02797955T DK1423525T3 DK 1423525 T3 DK1423525 T3 DK 1423525T3 DK 02797955 T DK02797955 T DK 02797955T DK 02797955 T DK02797955 T DK 02797955T DK 1423525 T3 DK1423525 T3 DK 1423525T3
Authority
DK
Denmark
Prior art keywords
recombinant mva
recombinant
structural
antigens
producing
Prior art date
Application number
DK02797955T
Other languages
English (en)
Inventor
Gerd Sutter
Volker Erfle
Caroline Staib
Yuan Wang
Guangdi Li
Lixin Zhu
Original Assignee
Helmholtz Zentrum Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of DK1423525T3 publication Critical patent/DK1423525T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02797955T 2001-09-05 2002-09-05 Rekombinant MVA, der kan eksprimere HCV-strukturantigener DK1423525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10143490A DE10143490C2 (de) 2001-09-05 2001-09-05 Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
PCT/EP2002/009958 WO2003023042A1 (de) 2001-09-05 2002-09-05 Rekombinantes mva mit der fähigkeit zur expression von hcv struktur-antigenen

Publications (1)

Publication Number Publication Date
DK1423525T3 true DK1423525T3 (da) 2008-12-01

Family

ID=7697788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02797955T DK1423525T3 (da) 2001-09-05 2002-09-05 Rekombinant MVA, der kan eksprimere HCV-strukturantigener

Country Status (10)

Country Link
US (4) US20050019347A1 (da)
EP (1) EP1423525B1 (da)
JP (1) JP4056472B2 (da)
CN (1) CN100375786C (da)
AT (1) ATE403007T1 (da)
DE (2) DE10143490C2 (da)
DK (1) DK1423525T3 (da)
HK (1) HK1074643A1 (da)
RU (1) RU2270860C2 (da)
WO (1) WO2003023042A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
US8058049B2 (en) * 2006-06-20 2011-11-15 Transgene S.A. Process for producing poxviruses and poxvirus compositions
JP5584407B2 (ja) * 2008-03-07 2014-09-03 公益財団法人東京都医学総合研究所 Ｃ型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス
EP2353610A4 (en) * 2008-11-19 2013-12-11 Avi Mex S A De C V Lab RECOMBINANT INACTIVATED VIRUS VECTOR VACCINE
CN103757032B (zh) * 2014-01-28 2017-06-06 中国人民解放军第三0二医院 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法
US11008368B2 (en) * 2019-07-26 2021-05-18 The Scripps Research Institute Engineered HCV E2 immunogens and related vaccine compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
WO1996004301A2 (en) * 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO2000026385A1 (en) * 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
CA2372709C (en) * 1999-05-28 2011-10-25 Stefan Wintersperger Vector for integration of heterologous sequences into poxviral genomes
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
AR035869A1 (es) * 2001-04-24 2004-07-21 Innogenetics Nv Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
DE10144664B4 (de) * 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
ATE403005T1 (de) * 2003-02-18 2008-08-15 Helmholtz Zentrum Muenchen Rekombinantes mva und verfahren zur erzeugung davon
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US20080286752A1 (en) * 2005-04-08 2008-11-20 The Trustees Of Columbia University In The City Of New York Methods for the production of HCV, assaying HCV entry, and screening drugs and cellular receptors for HCV

Also Published As

Publication number Publication date
US20090238843A1 (en) 2009-09-24
RU2004106592A (ru) 2005-07-10
RU2270860C2 (ru) 2006-02-27
US20130089569A1 (en) 2013-04-11
US20050019347A1 (en) 2005-01-27
DE50212580D1 (de) 2008-09-11
JP4056472B2 (ja) 2008-03-05
WO2003023042A1 (de) 2003-03-20
CN100375786C (zh) 2008-03-19
US20110293656A1 (en) 2011-12-01
DE10143490A1 (de) 2003-04-24
EP1423525A1 (de) 2004-06-02
CN1610748A (zh) 2005-04-27
JP2005502362A (ja) 2005-01-27
WO2003023042A9 (de) 2003-12-11
ATE403007T1 (de) 2008-08-15
EP1423525B1 (de) 2008-07-30
DE10143490C2 (de) 2003-12-11
HK1074643A1 (en) 2005-11-18

Similar Documents

Publication Publication Date Title
HK1074643A1 (en) Recombinant mva capable of expressing structural hcv antigens
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE69834671D1 (de) Immunantwort gegen HPV Antigene hervorgerufen von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einem Expressionsvektor fähig zur Expression dieser Proteine
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
UY25146A1 (es) Proteínas de fusión hpv comprendiendo una proteína e6, e7 o e6e7 fusionada con una proteína d de haemophilus influenzae b o derivados de la misma y composiciones para uso como vacunas que las comprenden
ATE350057T1 (de) Impfstoffzusammesetzung
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
MXPA05005202A (es) Vacuna.
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2003062374A3 (en) Synthetic genes for malarial proteins and methods of use
DK1416956T3 (da) Autologe T-celle-vaccinematerialer samt fremgangsmåde til deres fremstilling
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
ATE487489T1 (de) Rekombinante intrazellulärepathogen-immunogene zusammensetzungen und anwendungsverfahren
EP1090995A3 (en) Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
WO2002038769A3 (de) Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen
WO2006067469A3 (en) Compositions comprising opa protein epitopes
ITRM20010332A1 (it) Vaccini a subunita' e procedimenti per la loro produzione.